Pfizer set to acquire obesity drugmaker Metsera in $7.3 billion deal

Anabelle Colaco
25 Sep 2025, 09:41 GMT+10

Pfizer is close to striking a US$7.3 billion deal to acquire anti-obesity drugmaker Metsera, according to a Financial Times report
The U.S. pharmaceutical giant would pay $47.50 in cash per Metsera share, with an additional $22.50 tied to performance milestones, the report said
Neither Pfizer nor Metsera responded to requests for comment outside regular business hours

NEW YORK CITY, New York: Pfizer is close to striking a US$7.3 billion deal to acquire anti-obesity drugmaker Metsera, according to a Financial Times report on September 21 citing unnamed sources.

The U.S. pharmaceutical giant would pay $47.50 in cash per Metsera share, with an additional $22.50 tied to performance milestones, the report said. An announcement could come as early as this week.

The report could not be immediately confirmed. Neither Pfizer nor Metsera responded to requests for comment outside regular business hours.

Watch latest videos

News RELEASES

Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to North Carolina Daily.

More Information

Section